(b)(4).The device was not returned for analysis.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Additionally, a review of the complaint history did not indicate a lot specific quality issue.It was reported xience alpine stent delivery system (sds) was used after expiration of the device.It should be noted that the xience alpine everolimus eluting coronary stent system states: note the product ¿use by¿ date.In this case, it does not appear the instructions for use deviation related to use after expiration contributed to the reported event.The investigation was unable to determine a conclusive cause for the reported failure to advance.There is no indication of a product quality issue with respect to manufacture, design or labeling; therefore, no product-related corrective action will be implemented in this case.
|
It was reported that the procedure was to treat a moderately tortuous, de novo lesion in the left anterior descending (lad) artery.A 2.75x15mm xience alpine drug eluting stent (des) could not advance an unspecified guide wire as the entry notch was blocked.There was no adverse patient effect and no clinically significant delay in the procedure.Upon review of this complaint, it was noted that the stent system was attempted to be used after expiration, a xience sierra device was used to successfully complete the procedure.No additional information was provided.
|